MP
INDV icon

Mangrove Partners’s Indivior Pharmaceuticals INDV Stock Holding History

Mangrove Partners’s Portfolio INDV Stock Details INDV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$83.6M Sell
2,742,434
-3,575
-0.1% -$118K 6.76% 1
2025
Q4 		$98.5M Buy
2,746,009
+3,575
+0.1% +$109K 8.03% 1
2025
Q3 		$66.1M Buy
2,742,434
+469,766
+21% +$9.83M 4.89% 2
2025
Q2 		$33.5M Buy
2,272,668
+1,559,870
+219% +$18.2M 3.6% 10
2025
Q1 		$6.79M Buy
+712,798
New +$7.49M 0.73% 34
2024
Q4 		– Sell
-1,156,010
Closed -$11.3M – 177
2024
Q3 		$11.3M Buy
+1,156,010
New +$13.5M 0.97% 31

Other funds holding INDV

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
OCM
Oaktree Capital Management Los Angeles, California $6.56B AUM 42.97% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Mangrove Partners's INDV Position: Q1 2026 in Review

Mangrove Partners reduced its Indivior Pharmaceuticals (INDV) stake by 0.13% in Q1 2026, selling an estimated $118K and leaving 2,742,434 shares worth $83.6M. The position accounts for 6.76% of the portfolio, ranked #1.

Mangrove Partners first reported a position in INDV in Q3 2024 and has held it in 6 quarters since. The position peaked at $98.5M in Q4 2025. 289 funds tracked by Wall St. Rank hold INDV as of Q1 2026.

  • Mangrove Partners held 2,742,434 shares of Indivior Pharmaceuticals worth $83.6M as of Q1 2026.
  • Mangrove Partners sold 3,575 Indivior Pharmaceuticals shares in Q1 2026, an estimated $118K.
  • Indivior Pharmaceuticals made up 6.76% of Mangrove Partners's portfolio in Q1 2026, its #1 holding.
  • Mangrove Partners first reported a position in Indivior Pharmaceuticals in Q3 2024 and has held it in 6 quarters since.
  • Mangrove Partners's Indivior Pharmaceuticals position peaked at $98.5M in Q4 2025.
  • 289 funds tracked by Wall St. Rank held Indivior Pharmaceuticals as of Q1 2026.

Based on Mangrove Partners's 13F filing for Q1 2026, filed 15 May 2026.